Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease
2023-507330-24-00Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of ibrutinib in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Part A: Pharmacokinetics (AUC) of ibrutinib to determine recommended pediatric equivalent dose (RPED), Part B: Pharmacokinetics (AUC) of ibrutinib and 1 more. Started Apr 2024; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2023-507330-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507330-24-00.